Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.49 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131563 | 0.86 | RAB9A (0.54) | CASRPOLBRAB9AALDH1A1NPC1 | |
| SCHEMBL84441 | 0.83 | TSHR (0.53) | CASRPOLBRAB9APFKFB3PFKFB4 | |
| SCHEMBL27616133 | 0.81 | CYP4F2 (0.58) | CASRADRB2ADRB1ADRB3POLB | |
| SCHEMBL181739 | 0.80 | RAB9A (0.59) | CASRPOLBHSD17B10EGFRMAPK1 | |
| SCHEMBL16980505 | 0.80 | SMN1; SMN2 (0.50) | RAB9AHTR7MAPTMEN1KMT2A | |
| SCHEMBL18392373 | 0.80 | HSD17B10 (0.56) | CASRPOLBHSD17B10EGFRMAPK1 | |
| SCHEMBL20096465 | 0.80 | RAB9A (0.59) | CASRPOLBHSD17B10EGFRMAPK1 | |
| SCHEMBL25933608 | 0.78 | HTR7 (0.58) | POLBHSD17B10EGFRMAPK1RAB9A | |
| SCHEMBL18552696 | 0.78 | POLB (0.68) | CASRPOLBHSD17B10EGFRMAPK1 | |
| SCHEMBL14368018 | 0.78 | MTNR1A (0.61) | MAPTMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334313-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1542667-B1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7902241-B2 | 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes | PTC THERAPEUTICS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-7405233-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1542667-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004009558-A2 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS, THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASES CAUSED BY SUCH MUTATIONS | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | CASR 2522/4885ADRB2 2795/4885ADRB1 2299/4885 |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | CASR 2522/4885ADRB2 2795/4885ADRB1 2299/4885 |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | CASR 2522/4885ADRB2 2795/4885ADRB1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.